Back to results
US 11,513,131 B2Granted
Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof
AssigneeGlobal Genomics Group, LLC
InventorsBradley O. Brown, Idean B. Marvasty, Szilard Voros
Life of this patent
Estimating the term…
Abstract
The invention, in some aspects, relates to methods for diagnosing cardiovascular disease, and/or detecting cardiovascular disease in a patient, and more particularly to methods of using blood-based biomarkers and their combinations to identify patients at risk of having cardiovascular disease (e.g., coronary atherosclerosis).
Claims11
A method of diagnosing atherosclerotic coronary artery disease in a human subject, the method comprising:
- decomposing lipoproteins other than low density lipoproteins (LDL) from a blood sample obtained from a human subject, yielding a LDL particle sample;
- measuring the level of low density lipoprotein triglycerides (LDL-TG) in the LDL particle sample;
- comparing the measured level of LDL-TG in the LDL particle sample with one or more reference samples, wherein the one or more reference samples are representative of at least one individual not suffering from atherosclerotic coronary artery disease;
- identifying the human subject as having atherosclerotic coronary artery disease if the level of LDL-TG in the LDL particle sample is elevated as compared to the level of LDL-TG in the one or more reference samples, and
- administering a treatment for atherosclerotic coronary artery disease to the subject identified as having atherosclerotic coronary artery disease, wherein the treatment is selected from the group consisting of:
- a peroxisome proliferator-activated receptor (PPAR)-alpha agonist, a PPAR gamma agonist, and niacin.
3 more elements
A method of diagnosing atherosclerotic coronary artery disease in a human subject, the method comprising:
- decomposing lipoproteins other than low density lipoproteins (LDL) from a blood sample obtained from a human subject, yielding a LDL particle sample;
- measuring the level of low density lipoprotein triglycerides (LDL-TG) in the LDL particle sample;
- measuring the level of at least one analyte selected from the group consisting of:
- triglycerides, total cholesterol, low density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, apolipoprotein B (apoB), interleukin 6 (IL-6), symmetric dimethylarginine (SDMA), apolipoprotein B48 (apoB48), palmitoleic acid (POA), small dense LDL (sd-LDL), alkaline phosphatase (ALP) and asymmetric dimethylarginine (ADMA),
- comparing the measured level of LDL-TG in the LDL particle sample and the level of the at least one analyte with one or more reference samples, wherein the one or more reference samples are representative of at least one individual not suffering from atherosclerotic coronary artery disease;
- and
- identifying the human subject as having atherosclerotic coronary artery disease if the levels of LDL-TG in the LDL particle sample and the at least one analyte are both elevated as compared to the levels of LDL-TG and the at least one analyte in the one or more reference samples, and
- administering a treatment for atherosclerotic coronary artery disease to the subject identified as having atherosclerotic coronary artery disease, wherein the treatment is selected from the group consisting of:
- a peroxisome proliferator-activated receptor (PPAR)-LDL, alpha agonist, a PPAR gamma agonist, and niacin.
6 more elements
Dependencies are inferred from the claim text.